Biogen prices Spinraza

Biogen Inc. (NASDAQ:BIIB) priced spinal muscular atrophy (SMA) drug Spinraza nusinersen at a wholesale acquisition cost (WAC) of $125,000 per vial, spokesperson Matt Fearer told BioCentury. Based on Spinraza's dosing schedule, the drug would cost $750,000 the first year and $375,000 in each subsequent year.

Last week, FDA approved Spinraza to treat adults and children with SMA. Biogen has rights to the compound from Ionis Pharmaceuticals Inc. (NASDAQ:IONS) (see BioCentury Extra, Dec. 23)...